{
  "meta": {
    "title": "Hematology_Part_2",
    "url": "https://brainandscalpel.vercel.app/hematology-part-2-7cf4394d.html",
    "scrapedAt": "2025-11-30T11:13:03.890Z"
  },
  "questions": [
    {
      "id": 1,
      "choices": [
        {
          "id": 1,
          "text": "<p><span style=\"font-size:12.0pt;\">Deletion 17</span></p>"
        },
        {
          "id": 2,
          "text": "<p><span style=\"font-size:12.0pt;\">Deletion 11</span></p>"
        },
        {
          "id": 3,
          "text": "<p><span style=\"font-size:12.0pt;\">Deletion 13</span></p>"
        },
        {
          "id": 4,
          "text": "<p><span style=\"font-size:12.0pt;\">Trisomy 12</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which cytogenetic abnormality in CLL is associated with good prognosis?</span></p>",
      "unique_key": "DT1198101",
      "question_audio": null,
      "question_video": null,
      "map_id": 1198101,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p>The presence of <strong>deletion 13</strong> in CLL is associated with good prognosis.</p>\n<ul>\n<li>Cytogenetic alterations, alongside IGHV mutation status, serve as key <strong>prognostic markers </strong>in chronic lymphocytic leukemia (CLL).</li>\n<li>These abnormalities are commonly detected using FISH, though metaphase karyotyping also provides valuable insights.</li>\n<li>Among the most significant findings are del(13q14.3), trisomy 12, del(11q22.3), and del(17p13.1).</li>\n<li><strong>Isolated deletion of 13q14.3</strong>, often undetectable by routine karyotyping, is linked with <strong>favorable prognosis </strong>and long survival.</li>\n<li>In contrast, trisomy 12 correlates with intermediate outcomes. (Option D ruled out)</li>\n<li>Deletion of 11q22.3, involving the <strong>ATM gene</strong>, tends to occur in younger individuals with bulky lymphadenopathy and portends a more aggressive disease course and worse outcomes. (Option B ruled out)</li>\n<li>Deletion of 17p13.1, affecting the <strong>TP53 gene</strong>, signifies the most unfavorable prognosis with rapid progression, treatment resistance, and reduced survival. (Option A ruled out)</li>\n<li>Complex karyotypes which are defined by the presence of three or more cytogenetic abnormalities also predict poor response and reduced survival.</li>\n</ul>",
      "correct_choice_id": 3,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 2,
      "choices": [
        {
          "id": 11,
          "text": "<p><span style=\"font-size:12.0pt;\">MYC</span></p>"
        },
        {
          "id": 12,
          "text": "<p><span style=\"font-size:12.0pt;\">BCL-2</span></p>"
        },
        {
          "id": 13,
          "text": "<p><span style=\"font-size:12.0pt;\">BCL-6</span></p>"
        },
        {
          "id": 14,
          "text": "<p><span style=\"font-size:12.0pt;\">BCL-1</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Triple hit lymphoma includes all except?</span></p>",
      "unique_key": "DT1198107",
      "question_audio": null,
      "question_video": null,
      "map_id": 1198107,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p>Triple hit lymphoma involves chromosomal rearrangements in MYC, BCL-2, and BCL-6.</p>\n<ul>\n<li><strong>Double-hit lymphomas</strong> are a subset of B-cell lymphomas and are defined by chromosomal rearrangements involving the <strong>MYC gene</strong> along with either <strong>BCL2</strong> or<strong> BCL6</strong>.</li>\n<li>These genetic alterations are associated with a highly aggressive clinical course and <strong>very poor prognosis</strong>.</li>\n<li>Triple-hit lymphomas, although even rarer and not yet formally categorized by the WHO, exhibit additional chromosomal rearrangements involving <strong>MYC, BCL2, and BCL6</strong>.</li>\n<li>These lymphomas share intermediate features between DLBCL and Burkitt lymphoma (BL) in terms of morphology, immunophenotype, and genetics.</li>\n<li>Their prognosis is significantly worse than either DLBCL or BL alone, making their identification clinically crucial since they require different therapeutic approaches.</li>\n<li>Accurate diagnosis often involves <strong>cytogenetic studies</strong>, especially in cases presenting with high-grade features and a high proliferative index.</li>\n</ul><p><a href=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC3954668/\" target=\"_blank\">https://pmc.ncbi.nlm.nih.gov/articles/PMC3954668/</a></p>",
      "correct_choice_id": 14,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 3,
      "choices": [
        {
          "id": 21,
          "text": "<p><span style=\"font-size:12.0pt;\">&beta; -Thalassemia major</span></p>"
        },
        {
          "id": 22,
          "text": "<p><span style=\"font-size:12.0pt;\">Homozygosity for hemoglobin E (HbEE)</span></p>"
        },
        {
          "id": 23,
          "text": "<p><span style=\"font-size:12.0pt;\">Hemoglobin H (HbH) disease</span></p>"
        },
        {
          "id": 24,
          "text": "<p><span style=\"font-size:12.0pt;\">Hydrops fetalis</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">An 18-year-old woman from Pakistan is admitted for evaluation of chronic severe microcytic and hypochromic anemia. Her hemoglobin levels have generally been in the range of 7 to 10 g/dL, and she recalls needing blood transfusions only twice in her life, on both occasions after traumatic bone fractures. Physical examination shows marked hepatosplenomegaly; laboratory test abnormalities include indirect hyperbilirubinemia. HbA2 and HbE levels are found to be normal. What is the most likely diagnosis?</span></p>",
      "unique_key": "DT1198182",
      "question_audio": null,
      "question_video": null,
      "map_id": 1198182,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p>The clinical picture is most consistent with hemoglobin H (HbH) diseases.</p>\n<ul>\n<li><strong>Alpha-thalassemia</strong> arises due to inherited deletions that impair or abolish the synthesis of <strong>alpha-globin chains</strong>.</li>\n<li>Each person normally has<strong> four alpha-globin genes</strong>. The disease severity is directly proportional to the number of affected genes. Unlike beta-thalassemia, <strong>gene deletions</strong> and not point mutations are the usual culprits.</li>\n<li>Alpha-thalassemia is predominantly found in people from<strong> tropical</strong> and subtropical regions including South and Southeast Asia, Africa, and China. A particularly important clinical variant, HbH disease, is most common in<strong> Southern China</strong> and <strong>Southeast Asia</strong>.</li>\n<li>The condition is classified based on how many alpha-globin genes are deleted or malfunctioning:</li>\n</ul><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20250912b528f398-7f8d-4050-a489-06ab15fce54e.png\"><ul>\n<li>The lack of alpha chains results in unpaired globins (&gamma; in fetuses and &beta; in adults), forming <strong>unstable tetramers</strong> (Hb Bart's or HbH) that are inefficient in oxygen delivery and prone to precipitating in red cells. This leads to hemolysis, splenic sequestration, and impaired erythropoiesis.</li>\n<li>Alpha-thalassemia is suspected when there is <strong>microcytic hypochromic anemia</strong> with <strong>near-normal hemoglobin</strong> and no iron deficiency.</li>\n<li>HbH disease is identified by the presence of HbH or Hb Bart's (detected by HPLC), and the characteristic <strong>red cell inclusions</strong> visible with brilliant cresyl blue stain. Antenatal diagnosis requires genetic analysis.</li>\n<li>HbH disease presents with variable severity and can include <strong>hepatosplenomegaly</strong>, <strong>jaundice</strong>, facial bone changes, and growth delay in many cases.</li>\n<li>Hydrops fetalis leads to fetal anemia, generalized edema, and hepatosplenomegaly, requiring transfusions for survival and potentially hematopoietic stem cell transplantation. (Option C ruled out)</li>\n</ul>\n<p><strong>Explanation of other options:</strong></p>\n<p>&beta; -Thalassemia major (Option A): A transfusion dependent form of &beta; -Thalassemia which also requires iron chelation to prevent toxicity. HbA2 levels are elevated.</p>\n<p><strong>Homozygosity for hemoglobin E (HbEE) (Option B):</strong> Hemoglobin E (HbE), characterized by a glutamic acid to lysine substitution at position 27 of the beta chain, is a prevalent variant. HbE disease is characterized by an HbE fraction of 85 - 95%.</p>",
      "correct_choice_id": 23,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 4,
      "choices": [
        {
          "id": 31,
          "text": "<p><span style=\"font-size:12.0pt;\">Haemarthrosis</span></p>"
        },
        {
          "id": 32,
          "text": "<p><span style=\"font-size:12.0pt;\">Bleeding into the gastrointestinal tract</span></p>"
        },
        {
          "id": 33,
          "text": "<p><span style=\"font-size:12.0pt;\">Muscular haematoma</span></p>"
        },
        {
          "id": 34,
          "text": "<p><span style=\"font-size:12.0pt;\">Oral mucosal bleeding</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A patient with systemic lupus erythematosus (SLE) and immune thrombocytopenic purpura (ITP) presents with a platelet count of 5000/&mu;L. Which of these is the most likely presenting symptom?</span></p>",
      "unique_key": "DT1198191",
      "question_audio": null,
      "question_video": null,
      "map_id": 1198191,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p>A patient with immune thrombocytopenic purpura and SLE is likely to present with oral mucosal bleeding due to the low platelet count.</p>\n<ul>\n<li>A platelet count below 150,000/&mu;L is considered thrombocytopenia. When levels fall between 20,000 to 50,000/&mu;L, there is increased risk of bleeding after trauma.</li>\n<li>Counts under 20,000/&mu;L can lead to spontaneous, nontraumatic bleeding. In isolated thrombocytopenia, prothrombin time (PT) and partial thromboplastin time (PTT) remain normal.</li>\n<li>Hemorrhages tend to affect small vessels, with frequent bleeding seen in the <strong>skin </strong>and <strong>mucosal surfaces</strong> of the gastrointestinal and genitourinary tracts. The most serious risk is intracranial hemorrhage, especially in those with severely low platelet counts.</li>\n<li>Chronic ITP is an autoimmune condition characterized by the destruction of platelets due to autoantibodies, most commonly of the IgG type.</li>\n<li>These antibodies target platelet membrane glycoproteins (mainly IIb-IIIa or Ib-IX), leading to opsonization and phagocytosis by splenic macrophages.</li>\n<li>It may occur without an identifiable trigger (primary) or secondary to <strong>systemic lupus erythematosus</strong>, HIV, or B-cell malignancies like CLL.</li>\n<li>The antibodies bind to platelets in the circulation and are recognized by Fc receptors on phagocytes, <strong>promoting platelet clearance</strong>, especially in the spleen.</li>\n<li><strong>Splenectomy </strong>often improves platelet counts by removing the site of destruction and a source of antibody production.</li>\n<li>It typically affects adult women under 40, with a 3:1 female-to-male ratio. The disease develops gradually and is marked by mucocutaneous bleeding such as petechiae, ecchymoses, easy bruising, epistaxis, gum bleeding, melena, hematuria, or heavy menstrual bleeding.</li>\n<li>Serious bleeding like intracerebral hemorrhage is rare. Splenomegaly and lymphadenopathy are usually absent in primary ITP and suggest alternative diagnoses.</li>\n<li>Isolated thrombocytopenia is seen with <strong>normal PT and PTT</strong>. Bone marrow may show increased or normal megakaryocytes, and the presence of<strong> large platelets</strong> in peripheral smear is considered supportive. Platelet autoantibody tests lack reliability and are not routinely used. Diagnosis is made by excluding other causes.</li>\n<li>Clotting disorders, whether inherited or acquired, often present with <strong>large bruises</strong> (ecchymoses),<strong> deep hematomas</strong>, or prolonged bleeding following trauma or surgery.</li>\n<li>Unlike thrombocytopenia, these disorders tend to cause bleeding <strong>into the </strong>gastrointestinal and urinary systems, as well as into joints (hemarthrosis), especially after minimal stress. (Options A, B, and C ruled out)</li>\n<li>Common examples include extended bleeding after dental procedures or joint bleeds from minor activities.</li>\n</ul><br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20250912848bcf87-0195-442b-96df-352df4b10e43.png\">",
      "correct_choice_id": 34,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 5,
      "choices": [
        {
          "id": 41,
          "text": "<p><span style=\"font-size:12.0pt;\">Apixaban</span></p>"
        },
        {
          "id": 42,
          "text": "<p><span style=\"font-size:12.0pt;\">Bivalirudin</span></p>"
        },
        {
          "id": 43,
          "text": "<p><span style=\"font-size:12.0pt;\">Dabigatran</span></p>"
        },
        {
          "id": 44,
          "text": "<p><span style=\"font-size:12.0pt;\">Dalteparin</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following anticoagulants has a mechanism of action involving antithrombin-dependent inhibition of thrombin and factor Xa?</span></p>",
      "unique_key": "DT1198208",
      "question_audio": null,
      "question_video": null,
      "map_id": 1198208,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p>The mechanism of action of<strong> dalteparin</strong> is antithrombin-dependent inhibition of thrombin and factor Xa.</p>\n<ul>\n<li><strong>Low-molecular-weight heparins (LMWH)</strong>, such as dalteparin and enoxaparin, are anticoagulants used primarily for acute coronary syndromes and coronary interventions.</li>\n<li>They act by <strong>binding to antithrombin</strong> and enhancing its inhibition of coagulation factors, especially factor Xa and to a lesser degree, thrombin (factor IIa).</li>\n<li>Unlike unfractionated heparin, LMWH has a longer half-life, better bioavailability, and is primarily cleared renally, necessitating monitoring in renal impairment due to potential accumulation.</li>\n<li>Dalteparin has a more predictable anticoagulant effect, so routine monitoring is typically not required, but certain populations like those with <strong>renal dysfunction</strong>, obesity, pregnancy, or children may need individualized monitoring.</li>\n<li>Heparin, LMWH, and fondaparinux <strong>lack intrinsic anticoagulant activity</strong> but accelerates the inhibition of coagulation proteases by binding to antithrombin.</li>\n<li>Because LMWH molecules are shorter, many cannot simultaneously bind thrombin and antithrombin, resulting in a higher anti-factor Xa to anti-factor IIa activity ratio, typically between 2:1 and 3:1 depending on the preparation.</li>\n<li><strong>Platelet factor 4</strong>, a positively charged protein released from alpha granules during platelet activation, binds to heparin and interferes with its ability to engage with antithrombin.</li>\n<li>This interaction can reduce heparin's effectiveness near thrombi rich in platelets. In contrast, low-molecular-weight heparins (LMWH) and fondaparinux exhibit a <strong>weaker affinity for platelet factor 4</strong>, allowing them to maintain their anticoagulant activity more effectively in thrombus rich regions.</li>\n</ul>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V2NEETPGMCQ/202403278845c693-cb0f-4c6d-b556-22ac22955c6a.jpg\">\n<p>PCC: Prothrombin Complex Concentrates</p>\n<p>FFP: Fresh Frozen Plasma</p>\n<p><strong>Explanation of other options:</strong></p>\n<p><strong>Apixaban (Option A): </strong>Direct acting inhibitor of factor Xa used orally.</p>\n<p><strong>Bivalirudin (Option B): </strong>A parenteral direct thrombin inhibitor.</p>\n<p><strong>Dabigatran (Option C): </strong>A direct thrombin inhibitor used orally.</p>",
      "correct_choice_id": 44,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 6,
      "choices": [
        {
          "id": 51,
          "text": "<p><span style=\"font-size:12.0pt;\">Immune-mediated destruction of platelets via anti-GPIIb/IIIa antibodies</span></p>"
        },
        {
          "id": 52,
          "text": "<p><span style=\"font-size:12.0pt;\">Formation of microthrombi due to deficient vWF cleavage by ADAMTS13</span></p>"
        },
        {
          "id": 53,
          "text": "<p><span style=\"font-size:12.0pt;\">Shiga-toxin-mediated endothelial injury</span></p>"
        },
        {
          "id": 54,
          "text": "<p><span style=\"font-size:12.0pt;\">Antibody formation against PF4-heparin complex</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 30-year-old woman presents with fatigue, fever, and confusion. Laboratory investigations reveal anemia, thrombocytopenia, elevated lactate dehydrogenase (LDH), and schistocytes on peripheral smear. Coombs test is negative. Renal function is mildly impaired. Which of the following best explains the pathophysiology of this patientâ€™s condition?</span></p>",
      "unique_key": "DT1198215",
      "question_audio": null,
      "question_video": null,
      "map_id": 1198215,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p>The given clinical scenario of fever, confusion, thrombocytopenia, elevated lactate dehydrogenase, and schistocytes on peripheral smear suggests a diagnosis of<strong> thrombotic thrombocytopenic purpura </strong>which leads to <strong>formation of microthrombi due to deficient vWF cleavage by ADAMTS13</strong>.</p>\n<ul>\n<li>Thrombotic Thrombocytopenic Purpura (TTP) is a form of thrombotic microangiopathy characterized by microangiopathic hemolytic anemia (MAHA), thrombocytopenia,<strong> neurologic symptoms</strong>, <strong>renal dysfunction</strong>, and fever.</li>\n<li>Peripheral smear typically shows fragmented RBCs, while lab findings suggest hemolysis with elevated LDH, indirect hyperbilirubinemia, and reduced haptoglobin. Coagulation studies (PT, aPTT) usually remain within normal limits, distinguishing TTP from DIC.</li>\n<li>The pathogenesis of TTP revolves around a marked deficiency of the <strong>metalloprotease ADAMTS13 </strong>(activity &lt;10%), either due to inherited mutations (congenital TTP or cTTP/Upshaw-Schulman syndrome) or acquired autoantibodies (idiopathic TTP or iTTP).</li>\n<li>ADAMTS13 <strong>cleaves ultra-large von Willebrand factor</strong> (vWF) multimers.</li>\n<li>In its absence, these multimers accumulate, promoting <strong>abnormal platelet adhesion </strong>and aggregation, leading to widespread microthrombi.</li>\n<li>Though the ADAMTS13 deficiency is pivotal, clinical disease often requires an additional trigger such as <strong>pregnancy,</strong> infection, or inflammation.</li>\n<li>Idiopathic TTP is more common in women and individuals with HIV, with a higher incidence among Black individuals.</li>\n<li>Drug-induced forms may result from agents causing direct endothelial injury (e.g. mitomycin, tacrolimus, cyclosporine) or formation of autoantibodies (e.g. quinine, clopidogrel), and can mimic TTP pathophysiology. Quinine-related TTP tends to affect women more commonly.</li>\n<li>Therapeutic plasma exchange (TPE) is the cornerstone of treatment, continued until normalization of platelet counts and resolution of hemolysis. Glucocorticoids are often added as adjuncts, and rituximab helps reduce TPE duration and relapse rates.</li>\n</ul>\n<p><strong>Explanation of other options:</strong></p>\n<p><strong>Immune-mediated destruction of platelets via anti-GPIIb/IIIa antibodies (Option A): </strong>Implicated in immune thrombocytopenic purpura,</p>\n<p><strong>Shiga-toxin-mediated endothelial injury (Option C): </strong>Characteristic of typical hemolytic-uremic syndrome.</p>\n<p><strong>Antibody formation against PF4-heparin complex (Option D): </strong>Describes the pathogenesis of heparin induced thrombocytopenia.</p>",
      "correct_choice_id": 52,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 7,
      "choices": [
        {
          "id": 61,
          "text": "<p><span style=\"font-size:12.0pt;\">Vitamin K antagonism</span></p>"
        },
        {
          "id": 62,
          "text": "<p><span style=\"font-size:12.0pt;\">Direct factor X inhibition</span></p>"
        },
        {
          "id": 63,
          "text": "<p><span style=\"font-size:12.0pt;\">Indirect factor X inhibition</span></p>"
        },
        {
          "id": 64,
          "text": "<p><span style=\"font-size:12.0pt;\">Direct thrombin inhibition</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Idarucizumab is a monoclonal antibody useful for reversal of an anticoagulant. The mechanism of action of this anticoagulant is?</span></p>",
      "unique_key": "DT1198218",
      "question_audio": null,
      "question_video": null,
      "map_id": 1198218,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p><p>Idarucizumab is used for the reversal of effect of dabigatran which is an orally active <strong>direct thrombin inhibitor</strong>.</p>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V2NEETPGMCQ/20240327e39307e4-b7ea-4402-85f2-4a8d2703bd16.jpg\">\n<p>PCC: Prothrombin Complex Concentrates</p>\n<p>FFP: Fresh Frozen Plasma</p>\n<p><strong>Explanation of other options:</strong></p>\n<p><strong>Vitamin K antagonism (Option A): </strong>Describes the mechanism of action of warfarin. Reversal agents used for warfarin toxicity include vitamin K, prothrombin complex concentrates, and fresh frozen plasma.</p>\n<p><strong>Direct factor X inhibition (Option B):</strong> Exhibited by rivaroxaban, apixaban, and edoxaban for which andexanet alfa is used for reversal.</p>\n<p><strong>Indirect factor X inhibition (Option C):</strong> Shown by heparin, LMWH, and fondaparinux. Protamine sulfate is used to reverse effects of heparin.</p>",
      "correct_choice_id": 64,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 8,
      "choices": [
        {
          "id": 71,
          "text": "<p><span style=\"font-size:12.0pt;\">Alcoholic liver disease</span></p>"
        },
        {
          "id": 72,
          "text": "<p><span style=\"font-size:12.0pt;\">Aplastic anemia</span></p>"
        },
        {
          "id": 73,
          "text": "<p><span style=\"font-size:12.0pt;\">Primary myelofibrosis</span></p>"
        },
        {
          "id": 74,
          "text": "<p><span style=\"font-size:12.0pt;\">Hyposplenism</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">The blood film of a 67-year-old man is reported to show target cells and Howell-Jolly bodies. He is also noted to have leukocytosis and mild thrombocytosis. What is the most likely cause of this picture?</span></p>",
      "unique_key": "DT1198221",
      "question_audio": null,
      "question_video": null,
      "map_id": 1198221,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p>The given peripheral smear findings of target cells and Howell-Jolly bodies along leukocytosis and thrombocytosis are suggestive of<strong> hyposplenism</strong>.</p>\n<ul>\n<li>Hyposplenism refers to a state of reduced or absent splenic function, which may result from <strong>splenectomy </strong>or diseases such as sickle cell disease that lead to <strong>autoinfarction of the spleen</strong>.</li>\n<li>It is associated with the presence of <strong>Howell-Jolly bodies</strong> which are nuclear remnants seen in erythrocytes, indicative of impaired splenic filtration.</li>\n<li>Other erythrocyte abnormalities seen include <strong>target cells</strong>, basophilic stippling, anisocytosis, poikilocytosis, and occasional nucleated cells.</li>\n<li>Hyposplenism compromises immune surveillance and filtration, leading to <strong>leukocytosis</strong> and<strong> thrombocytosis</strong>, particularly in the initial postoperative period.</li>\n<li>Patients with hyposplenism are more susceptible to severe infections, especially from <strong>encapsulated bacteria</strong> like Streptococcus pneumoniae, Haemophilus influenzae, and Neisseria meningitidis.</li>\n<li>The risk of sepsis is highest in children under 20, particularly within the first 3 years after splenectomy.</li>\n<li>Preventive measures include <strong>vaccinations</strong> (preferably administered 2 weeks prior to splenectomy) and, in certain cases, prophylactic antibiotics like oral penicillin.</li>\n<li>The identification of hyposplenism is critical because of its associated high risk of infection and the need for preventive care, especially in those who are asplenic or functionally hyposplenic due to underlying hematologic or autoimmune disorders.</li>\n</ul>\n<p><strong>Explanations of other options:</strong></p>\n<p><strong>Alcoholic liver disease (Option A): </strong>Liver disease is associated with target cells and stomatocytes.</p>\n<p><strong>Aplastic anemia (Option B): </strong>The peripheral smear in aplastic anemia reveals <strong>large red blood cells</strong> with a reduced number of platelets and granulocytes. Reticulocytes are scarce or absent, and lymphocytes may appear normal or decreased. The presence of nucleated red blood cells suggests underlying marrow fibrosis or infiltration, while immature myeloid cells may point to leukemia or myelodysplastic syndrome (MDS). Abnormal platelet morphology indicates possible peripheral destruction or MDS.</p>\n<p><strong>Primary myelofibrosis (Option C):</strong> In primary myelofibrosis (PMF), the peripheral blood smear typically demonstrates signs of <strong>extramedullary hematopoiesis</strong>. Characteristic findings include <strong>teardrop-shaped red blood cells</strong>, nucleated red cells, and immature myeloid precursors such as myelocytes and promyelocytes. Myeloblasts may also be seen. These features reflect the marrow fibrosis and compensatory blood cell production occurring outside the bone marrow.</p>",
      "correct_choice_id": 74,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 9,
      "choices": [
        {
          "id": 81,
          "text": "<p><span style=\"font-size:12.0pt;\">Mantle cell lymphoma</span></p>"
        },
        {
          "id": 82,
          "text": "<p><span style=\"font-size:12.0pt;\">Chronic lymphocytic leukemia</span></p>"
        },
        {
          "id": 83,
          "text": "<p><span style=\"font-size:12.0pt;\">Diffuse large B-cell NHL</span></p>"
        },
        {
          "id": 84,
          "text": "<p><span style=\"font-size:12.0pt;\">Follicular lymphoma</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 68 year old man presents to his family physician with fever, night sweats and unexplained weight loss. Which one of the following is defined by low-grade, small lymphocytes with cleaved nuclear contours that are CD5 and cyclin D1 positive but CD23 negative?</span></p>",
      "unique_key": "DT1198226",
      "question_audio": null,
      "question_video": null,
      "map_id": 1198226,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p><strong>Mantle cell lymphoma</strong> tends to present with morphologically small lymphocytes with cleaved nuclear contours that are positive for CD5 but negative for CD23 and harbors the translocation t(11:14), which leads to overexpression of cyclin D1.</p>\n<ul>\n<li>Mantle cell lymphoma is an uncommon B-cell non-Hodgkin lymphoma with a male predominance and typical onset in the fifth to sixth decades.</li>\n<li>It is classified as an <strong>intermediate-grade lymphoma</strong> that is not usually curable with conventional therapies and often requires aggressive chemoimmunotherapy or stem cell transplantation.</li>\n<li>The median overall survival ranges from 5 to 10 years, with a particularly poor prognosis in the blastic variant, which is marked by <strong>high Ki-67 expression</strong>.</li>\n<li>A more indolent subtype with <strong>SOX11 negativity</strong>, low Ki-67, and splenomegaly but no lymphadenopathy behaves more like indolent NHLs.</li>\n<li>Mantle cell lymphoma is typically associated with <strong>t(11;14)</strong>(q13;q32) translocation, which juxtaposes the <strong>cyclin D1</strong> gene on chromosome 11 with the IGH locus on chromosome 14, resulting in <strong>overexpression of cyclin D1</strong> that promotes G1-to-S phase progression.</li>\n<li>Morphologically, the lymph node shows a homogeneous proliferation of <strong>small lymphocytes with irregular (often cleaved) nuclear contours</strong>, condensed chromatin, and scant cytoplasm. Large blast-like or centroblast-like cells and proliferation centers are absent.</li>\n<li>The tumor may form nodular or diffuse growth patterns and often involves extranodal sites such as bone marrow, GI tract (notably polyps), liver, and spleen.</li>\n<li>Immunophenotypically, MCL expresses <strong>cyclin D1</strong>, CD5, CD19, and CD20, but <strong>lacks CD10</strong> and<strong> CD23</strong>, helping to differentiate it from follicular lymphoma and CLL/SLL. Most cases express surface IgM or IgD.</li>\n<li>The blastic variant has high proliferation and poor prognosis, while those with TP53 mutations or complex karyotypes are considered high risk.</li>\n<li>Clinically, MCL presents with <strong>painless lymphadenopathy</strong> and may involve the spleen or gastrointestinal tract in about 50% of cases.</li>\n<li>Treatment options include BR (bendamustine and rituximab), often preferred over R-CHOP, with autologous stem cell transplant in eligible cases. Maintenance rituximab may prolong response.</li>\n</ul>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V2NEETPGMCQ/2024032765200454-76f3-44e2-a0cb-ff175ed51674.jpg\">\n<p><strong>Explanations of other options:</strong></p>\n<p><strong>Chronic lymphocytic leukemia (Option B): </strong>Chronic lymphocytic leukemia exhibits a characteristic immunophenotype marked by the expression of pan B-cell markers CD19 and CD20, along with<strong> CD23 </strong>and <strong>CD5</strong>, the latter normally found on a minor subset of B cells. These tumor cells typically show low levels of surface immunoglobulin (usually IgM or both IgM and IgD) and high expression of the anti-apoptotic protein BCL2.</p>\n<p><strong>Diffuse large B-cell NHL (Option C): </strong>Diffuse large B-cell lymphomas (DLBCL) typically express CD19 and CD20, with variable expression of germinal center markers like<strong> CD10</strong> and BCL6. Most tumor cells also display surface immunoglobulin. Morphologically the cells are<strong> large </strong>with an oval or round nucleus which appears vesicular due to margination of chromatin to the nuclear membrane.</p>\n<p><strong>Follicular lymphoma (Option D): </strong>Follicular lymphoma cells closely mimic normal germinal center B cells and typically express CD19, CD20, CD10, surface immunoglobulin, and BCL6. Unlike CLL/SLL and mantle cell lymphoma, they <strong>do not express CD5</strong>. Additionally, BCL2 is expressed in over 90% of cases, which contrasts with normal follicular center B cells that are BCL2-negative.</p>",
      "correct_choice_id": 81,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 10,
      "choices": [
        {
          "id": 91,
          "text": "<p><span style=\"font-size:12.0pt;\">Hematopoietic stem cell transplantation</span></p>"
        },
        {
          "id": 92,
          "text": "<p><span style=\"font-size:12.0pt;\">Immunosuppressive therapy with high-dose glucocorticoids</span></p>"
        },
        {
          "id": 93,
          "text": "<p><span style=\"font-size:12.0pt;\">Immunosuppressive therapy with horse anti-thymocyte globulin (ATG) followed by cyclosporin</span></p>"
        },
        {
          "id": 94,
          "text": "<p><span style=\"font-size:12.0pt;\">Eltrombopag</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">The first-line therapy for a 25-year old male patient with severe aplastic anemia is?</span></p>",
      "unique_key": "DT1198229",
      "question_audio": null,
      "question_video": null,
      "map_id": 1198229,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation: </strong></p>\n<p>The first-line therapy for a 25-year old male patient with severe aplastic anemia is <strong>hematopoietic stem cell transplantation</strong>.</p>\n<ul>\n<li>Severe acquired aplastic anemia may be managed through either hematopoietic stem cell transplantation or immunosuppressive therapy.</li>\n<li>Stem cell transplantation is <strong>preferred in younger patients</strong> with a fully matched sibling donor, while older individuals or those without a suitable donor are managed with<strong> immunosuppression using antithymocyte globulin (ATG) and cyclosporine</strong>. (Option C ruled out)</li>\n<li><strong>Glucocorticoids are not recommended</strong> as primary therapy, and suspected drug or chemical exposures should be discontinued. (OPtion B ruled out)</li>\n<li>If the disease is diagnosed early in a child or young adult, HLA typing should be initiated immediately, and blood transfusions from family members avoided to reduce sensitization.</li>\n<li>When no sibling donor is available, unrelated donors or cord blood may be considered, especially in pediatric cases. Transplantation from haploidentical donors is also emerging as a feasible option.</li>\n<li><strong>Eltrombopag</strong>, a thrombopoietin mimetic, is useful in <strong>refractory cases</strong> or as part of initial therapy. (Option D ruled out)</li>\n<li>Androgens may benefit some patients, particularly those with telomere shortening.</li>\n<li><strong>Supportive care</strong> includes prompt treatment of infections and transfusions to maintain adequate blood counts. Platelet transfusions aim to keep counts above 10,000/&mu;L, and menstrual suppression is necessary in thrombocytopenic females.</li>\n<li><strong>RBC transfusions</strong> are used to maintain hemoglobin at functional levels, with iron chelation added after approximately 50 transfusions to prevent iron overload.</li>\n</ul>",
      "correct_choice_id": 91,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 11,
      "choices": [
        {
          "id": 101,
          "text": "<p><span style=\"font-size:12.0pt;\">Chronic gastrointestinal tract bleeding</span></p>"
        },
        {
          "id": 102,
          "text": "<p><span style=\"font-size:12.0pt;\">High hepcidin levels inhibiting iron export from macrophages</span></p>"
        },
        {
          "id": 103,
          "text": "<p><span style=\"font-size:12.0pt;\">Reduced EPO production</span></p>"
        },
        {
          "id": 104,
          "text": "<p><span style=\"font-size:12.0pt;\">Gastrectomy</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 68-year-old woman with rheumatoid arthritis has been found to have low hemoglobin. Which of the following contributes to the development of anemia of chronic disease?</span></p>",
      "unique_key": "DT1198232",
      "question_audio": null,
      "question_video": null,
      "map_id": 1198232,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p><strong>High hepcidin levels inhibiting iron release from storage sites </strong>contributes to the development of anemia of chronic disease.</p>\n<ul>\n<li>Anemia of chronic disease, also termed anemia of inflammation (AI), is a common anemia associated with inflammatory, infectious, or neoplastic conditions.</li>\n<li>It is characterized by<strong> normal or increased iron stores</strong> but impaired iron utilization due to restricted iron delivery to the marrow.</li>\n<li>Laboratory findings typically include low serum iron, <strong>elevated serum ferritin</strong>, reduced transferrin saturation (15 - 20%), and low red cell protoporphyrin, with a <strong>hypoproliferative marrow</strong>.</li>\n<li><strong>Interleukin-1 (IL-1)</strong> reduces the production of erythropoietin (EPO) in response to anemia. It also <strong>impairs the erythroid marrow's responsiveness to EPO</strong> by promoting the release of interferon-gamma (IFN-&gamma;) from accessory cells.</li>\n<li>This suppression can be reversed with <strong>EPO administration</strong> both in vitro and in vivo. Additionally, tumor necrosis factor (TNF) diminishes EPO responsiveness by stimulating marrow stromal cells to release interferon-beta (IFN-&beta;).</li>\n</ul><br><img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/20250912cf8680cf-b480-4974-8a24-8f4c2a07073a.png\"><br><ul>\n<li><strong>Hepcidin</strong>, a key iron regulatory hormone <strong>elevated via IL-6 </strong>in inflammation, <strong>suppresses iron absorption and release</strong>, while cytokines like IL-1 and TNF reduce erythropoietin (EPO) responsiveness, leading to impaired erythropoiesis and shortened red cell lifespan.</li>\n<li>In patients with chronic conditions like cancer, anemia is usually <strong>normocytic and normochromic</strong>, whereas in long-standing inflammatory diseases such as rheumatoid arthritis or tuberculosis, it may present as <strong>microcytic hypochromic anemia</strong>.</li>\n<li>Though hypoproliferative in both, the variation in red cell indices arises from differing iron availability for hemoglobin synthesis.</li>\n</ul>\n<p><strong>Explanation of other options:</strong></p>\n<p><strong>Chronic gastrointestinal tract bleeding (Option A): </strong>Leads to iron deficiency anemia</p>\n<p><strong>Reduced EPO production(Option C): </strong>Explains anemia due to chronic kidney disease.</p>\n<p><strong>Gastrectomy (Option D): </strong>Gastrectomy can cause both iron deficiency anemia and megaloblastic anemia.</p>",
      "correct_choice_id": 102,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 12,
      "choices": [
        {
          "id": 111,
          "text": "<p><span style=\"font-size:12.0pt;\">Aplastic crisis</span></p>"
        },
        {
          "id": 112,
          "text": "<p><span style=\"font-size:12.0pt;\">Sequestration crisis</span></p>"
        },
        {
          "id": 113,
          "text": "<p><span style=\"font-size:12.0pt;\">Meningococcal sepsis</span></p>"
        },
        {
          "id": 114,
          "text": "<p><span style=\"font-size:12.0pt;\">Painful vaso-occlusive crisis</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 16-year-old boy with known sickle-cell disease is brought to the emergency department profoundly unwell. He has a temperature 39&deg;C, pulse rate 160 beats/min and blood pressure 70/40 mmHg. Examination reveals neck rigidity. Laboratory investigations reveal elevated WBC count, Hb levels of 8.6, and platelet count of 200,000/ mm3.</span></p>",
      "unique_key": "DT1198238",
      "question_audio": null,
      "question_video": null,
      "map_id": 1198238,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p>The given clinical scenario of fever, neck rigidity, elevated WBC count, and low blood pressure suggests a diagnosis of meningococcal sepsis.</p>\n<ul>\n<li>Patients with <strong>sickle-cell disease</strong> have compromised splenic function resulting from microvascular occlusion which puts them at risk of life-threatening infections from capsulated organisms such as <strong>Neisseria meningitidis</strong> (meningococcal meningitis).</li>\n<li>Sickle cell disease is an inherited disorder caused by a <strong>point mutation</strong> in the &beta;-globin gene, resulting in the production of hemoglobin S (HbS).</li>\n<li>This mutant hemoglobin polymerizes under low oxygen conditions, leading to red cell deformation, hemolytic anemia, <strong>microvascular occlusion</strong>, and tissue injury.</li>\n<li>The condition is most common in individuals of African descent with heterozygotes (sickle cell trait) showing resistance to Plasmodium falciparum malaria. Homozygous individuals produce mostly HbS and suffer from symptomatic disease.</li>\n<li>Sickle cell disease manifests with chronic hemolytic anemia (hematocrit 18-30%), reticulocytosis, hyperbilirubinemia, and frequent vaso-occlusive crises.</li>\n<li>These crises cause <strong>severe pain</strong> due to ischemic injury in various organs. Common sites include <strong>bones</strong>, <strong>lungs</strong> (acute chest syndrome), brain, spleen, and penis. (Option D ruled out)</li>\n<li>Complications include priapism, stroke, infections, <strong>autosplenectomy</strong>, and chronic organ damage. Sequestration crises and <strong>aplastic crises</strong> (due to parvovirus B19) may occur. Children are especially susceptible to infections by <strong>encapsulated organisms</strong> due to<strong> splenic dysfunction</strong>.</li>\n</ul>\n<p><strong>Explanation of other options:</strong></p>\n<p><strong>Aplastic crisis (Option A):</strong> Aplastic crises are triggered by parvovirus B19 infection, which temporarily halts red blood cell production, leading to an <strong>abrupt decline in hemoglobin levels</strong>.</p>\n<p><strong>Sequestration crisis (Option B): </strong>In children with functional spleens, sequestration crises arise from the sudden trapping of large numbers of sickled red blood cells in the spleen, resulting in <strong>rapid splenic enlargement</strong>, <strong>reduced blood volume</strong>, and potentially shock. These crises, along with acute chest syndrome, can be life-threatening and may necessitate urgent exchange transfusions.</p>\n<p><strong>Painful vaso-occlusive crisis (Option C):</strong> There is no history of joint pain or shortness of breath to suggest a vaso-occlusive painful crisis or sickle chest syndrome.</p>",
      "correct_choice_id": 113,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 13,
      "choices": [
        {
          "id": 121,
          "text": "<p><span style=\"font-size:12.0pt;\">Iron Deficiency</span></p>"
        },
        {
          "id": 122,
          "text": "<p><span style=\"font-size:12.0pt;\">Vitamin B12 deficiency</span></p>"
        },
        {
          "id": 123,
          "text": "<p><span style=\"font-size:12.0pt;\">Sideroblastic anemia</span></p>"
        },
        {
          "id": 124,
          "text": "<p><span style=\"font-size:12.0pt;\">Warm type autoimmune hemolytic anemia</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following conditions would result in a microcytic anemia with a normal/high ferritin?</span></p>",
      "unique_key": "DT1198250",
      "question_audio": null,
      "question_video": null,
      "map_id": 1198250,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p><strong>Sideroblastic anemia </strong>results in a microcytic anemia with a normal/high ferritin.</p>\n<p>The following table distinguishes the different causes of microcytic anemia.</p>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3fkkq5frqjyl8.cloudfront.net/V4/NEETPGUPDATEDMCQ/202509123f82c1ad-59f0-4982-8f70-74caa71ec501.png\"><p><strong>Explanation of other options:</strong></p>\n<p><strong>Iron Deficiency (Option A): </strong>Iron deficiency anemia is characterised by reduced serum ferritin levels.</p>\n<p><strong>Vitamin B12 deficiency (Option B): </strong>Vitamin B12 deficiency causes megaloblastic macrocytic anemia.</p>\n<p><strong>Warm type autoimmune hemolytic anemia (Option D): </strong>Hemolytic anemias usually lead to <strong>macrocytosis</strong>.</p>",
      "correct_choice_id": 123,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 14,
      "choices": [
        {
          "id": 131,
          "text": "<p><span style=\"font-size:12.0pt;\">IgA levels of 40 g/L with no myeloma defining events</span></p>"
        },
        {
          "id": 132,
          "text": "<p><span style=\"font-size:12.0pt;\">A single lesion in bone or soft tissue confirmed by biopsy, showing the presence of clonal plasma cells</span></p>"
        },
        {
          "id": 133,
          "text": "<p><span style=\"font-size:12.0pt;\">Low levels of lgG monoclonal protein with clonal bone marrow cells < 10%</span></p>"
        },
        {
          "id": 134,
          "text": "<p><span style=\"font-size:12.0pt;\">Bone marrow plasmacytosis > 10% with no M protein in urine or serum</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following situations would be in keeping with a diagnosis of monoclonal gammopathy of uncertain significance (MGUS)?</span></p>",
      "unique_key": "DT1198256",
      "question_audio": null,
      "question_video": null,
      "map_id": 1198256,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p>Among the given options, low levels of lgG monoclonal protein with clonal bone marrow cells &lt; 10% is consistent with the diagnosis of monoclonal gammopathy of undetermined significance.<strong><br /> </strong></p>\n<ul>\n<li><strong>Monoclonal Gammopathy of Undetermined Significance (MGUS)</strong> is the most common plasma cell disorder, seen in about 3% of individuals over 50 and 5% of those over 70 years.</li>\n<li>It is characterized by serum monoclonal protein (non-IgM type) levels below<strong> 30 g/L</strong>, bone marrow clonal plasma cells under<strong> 10%</strong>, and <strong>absence of myeloma-defining events</strong> or amyloidosis related to plasma cell proliferation.</li>\n<li>Patients are asymptomatic by definition, but about 1% per year progress to symptomatic plasma cell neoplasms, usually multiple myeloma.</li>\n<li>The clonal plasma cells in MGUS often carry chromosomal abnormalities similar to those in multiple myeloma, indicating MGUS as a precursor stage.</li>\n<li>Therefore, regular monitoring of serum M protein and Bence Jones proteinuria is recommended.</li>\n</ul>\n<p><strong>Explanations of other options:</strong></p>\n<p><strong>IgA levels of 40 g/L with no myeloma defining events (Option A): </strong>Consistent with <strong>smoldering multiple myeloma</strong>, also called asymptomatic myeloma which defined by the presence of serum monoclonal protein (IgG or IgA)<strong> &ge;30 g/L </strong>or urinary monoclonal protein &ge;500 mg in 24 hours and/or clonal bone marrow plasma cells ranging between<strong> 10 - 60%,</strong> in the <strong>absence of any myeloma-defining event</strong>s or amyloidosis.</p>\n<p><strong>A single lesion in bone or soft tissue confirmed by biopsy, showing the presence of clonal plasma cells (Option B): </strong>Suggestive of<strong> solitary plasmacytom</strong>a which is defined by a single, biopsy-confirmed lesion in bone or soft tissue containing clonal plasma cells, while the remaining <strong>bone marrow shows no clonal involvement</strong>. Imaging studies such as skeletal survey and spine/pelvis MRI or CT appear normal except at the primary lesion site. There is no evidence of CRAB features which are hypercalcemia, renal failure, anemia, or other bone lesions which can be linked to a lymphoplasmacytic proliferative disorder.</p>\n<p><strong>Bone marrow plasmacytosis &gt; 10% with no M protein in urine or serum (Option D): </strong>Points to a diagnosis of <strong>nonsecretory myeloma </strong>which is characterized by the absence of detectable M protein in both serum and urine despite immunofixation testing. It involves &ge;10% clonal plasma cells in the bone marrow or the presence of a plasmacytoma, along with evidence of myeloma-associated organ damage.</p>",
      "correct_choice_id": 133,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 15,
      "choices": [
        {
          "id": 141,
          "text": "<p><span style=\"font-size:12.0pt;\">Whole blood transfusion</span></p>"
        },
        {
          "id": 142,
          "text": "<p><span style=\"font-size:12.0pt;\">Fresh frozen plasma</span></p>"
        },
        {
          "id": 143,
          "text": "<p><span style=\"font-size:12.0pt;\">Platelets</span></p>"
        },
        {
          "id": 144,
          "text": "<p><span style=\"font-size:12.0pt;\">Prothrombin complex concentrate</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 22-year-old man is admitted following a severe road traffic accident. He suffered significant blood loss at the scene. He is resuscitated with IV crystalloid and group O negative packed red cells. Intra-operatively the anesthetist phones you for advice. Bloods show: Hb: 6.6 g/dL; WBC: 11200/&mu;L; platelet count 83000/&mu;L; PT 28 seconds; APTT: 72 seconds; fibrinogen: 1.9 g/L. What is most appropriate to use to reduce his bleeding risk?</span></p>",
      "unique_key": "DT1198260",
      "question_audio": null,
      "question_video": null,
      "map_id": 1198260,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p>The likely diagnosis based on the given scenario is disseminated intravascular coagulation for which<strong> fresh frozen plasma </strong>is to be administered.</p>\n<ul>\n<li><strong>Disseminated Intravascular Coagulation </strong>(DIC) is an acquired, systemic disorder marked by widespread <strong>activation of the coagulation cascade</strong>, resulting in fibrin deposition, thrombus formation in small and midsize vessels, and subsequent organ dysfunction.</li>\n<li>This ongoing coagulation leads to the <strong>consumption of clotting factors and platelets</strong>, often accompanied by secondary hyperfibrinolysis, culminating in both thrombotic and hemorrhagic complications.</li>\n<li>Clinical features vary depending on severity and include <strong>petechiae</strong>, ecchymoses, bleeding from venipuncture sites, gastrointestinal or CNS hemorrhage, and signs of microvascular thrombosis causing multi-organ dysfunction.</li>\n<li>Laboratory findings typically reveal<strong> thrombocytopenia</strong>, <strong>prolonged PT </strong>and <strong>aPTT</strong>, elevated D-dimer, <strong>decreased fibrinogen levels</strong>, and schistocytes (fragmented red cells) on peripheral smear. Chronic DIC may show compensated parameters with mild thrombocytopenia and red cell fragmentation.</li>\n<li>DIC arises secondary to a wide variety of clinical conditions. The most common precipitating factor is <strong>sepsis</strong> (bacterial, viral, mycotic, parasitic, or rickettsial). Other causes include extensive burns, <strong>abruptio placentae</strong>, amniotic fluid embolism, septic abortion, snake bites, and ARDS.</li>\n<li><strong>Malignancies</strong>, especially mucin-producing adenocarcinomas and acute promyelocytic leukemia are also key triggers.</li>\n<li>Diagnosis is guided by clinical suspicion and confirmed using scoring systems that evaluate platelet count, PT, aPTT, D-dimer, and fibrinogen levels.</li>\n<li>Patients experiencing active bleeding or at significant risk of bleeding such as those undergoing invasive procedures or receiving chemotherapy should be given transfusion support. However, transfusions should not be used solely to correct mild to moderate abnormalities in coagulation tests. (Option A ruled out_</li>\n<li>Platelet transfusions are appropriate when platelet counts fall below 10,000-20,000/&mu;L. (Option C ruled out)</li>\n<li>If there is a need to restore fibrinogen and clotting factors, <strong>fresh frozen plasma</strong> (FFP), <strong>cryoprecipitate</strong>, or fibrinogen concentrates can be used, with the required amounts based on the extent of abnormalities in PT, aPTT, and fibrinogen levels.</li>\n<li>Fibrinogen levels should be maintained above 150 mg/dL, and PT should not be more than 3 seconds above the normal range. Vitamin K administration is advised.</li>\n<li>Antifibrinolytics may be considered in those with severe bleeding and a primary hyperfibrinolytic state, especially in chronic DIC associated with tumors or protein C pathway deficiencies.</li>\n</ul>\n<p><strong>Explanation of other options:</strong></p>\n<p><strong>Prothrombin complex concentrate (Option D): </strong>Prothrombin complex concentrates (PCCs) are plasma-derived factor preparations that were originally developed to provide factor VIII or IX for individuals with hemophilia. However, since they include vitamin K-dependent clotting factors, they are also utilized for<strong> reversing the effects of warfarin</strong> therapy.</p>",
      "correct_choice_id": 142,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 16,
      "choices": [
        {
          "id": 151,
          "text": "<p><span style=\"font-size:12.0pt;\">Acute lymphocytic leukemia</span></p>"
        },
        {
          "id": 152,
          "text": "<p><span style=\"font-size:12.0pt;\">Hairy cell leukemia</span></p>"
        },
        {
          "id": 153,
          "text": "<p><span style=\"font-size:12.0pt;\">Idiopathic thrombocytopenic purpura</span></p>"
        },
        {
          "id": 154,
          "text": "<p><span style=\"font-size:12.0pt;\">Infectious mononucleosis</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 56-year-old man presents to his physician complaining of chronic fatigue. He also notes that he has had a nonproductive cough for about 2 weeks, and has experienced several episodes of drenching night sweats. On examination, he has several large bruises on his extremities but recalls no injuries. Abdominal examination reveals massive enlargement of both the liver and the spleen, without any lymphadenopathy. Laboratory tests show:<br>WBC: 12,000/mm3 (Neutrophils 58% Eosinophils 7% Lymphocytes 30% Monocytes 0% Basophils 5%)<br>Hemoglobin 7.5 mg/dL<br>Platelet count 18,000/mm3<br>Peripheral blood smear on staining shows folded nuclei and on phase contrast microscopy reveals cells with cytoplasmic projections. <br>What is the patient's most likely diagnosis?</span></p>",
      "unique_key": "DT1198264",
      "question_audio": null,
      "question_video": null,
      "map_id": 1198264,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p>The given clinical features of fatigue, cough, night sweats, and laboratory findings with peripheral blood smear showing cells with irregular nuclei and cytoplasmic projects suggests a diagnosis of <strong>hairy cell leukemia</strong>.</p>\n<ul>\n<li>Hairy cell leukemia is an uncommon B-cell neoplasm that typically affects <strong>middle-aged males</strong> and accounts for around 2% of leukemias.</li>\n<li>It is marked by lymphoid cells with <strong>oval nuclei</strong>, abundant pale cytoplasm, and distinctive <strong>cytoplasmic projection</strong>s visible under phase-contrast microscopy.</li>\n<li>Clinically, patients often present with <strong>splenomegaly</strong>, <strong>pancytopenia</strong>, and <strong>monocytopenia</strong>, and bone marrow aspiration may yield a '<strong>dry tap</strong>' due to reticulin fibrosis.</li>\n<li>Immunophenotypically, the tumor cells express CD19, CD20, CD22, CD25, CD103, and <strong>annexin A1</strong>, and exhibit <strong>tartrate-resistant acid phosphatase</strong></li>\n<li>Nearly all cases harbor the <strong>BRAF V600E</strong> mutation, activating the MAPK pathway.</li>\n<li>Histologically, the marrow and spleen show diffuse infiltration by these cells, and hepatomegaly and portal triads may also be involved.</li>\n<li>Treatment includes nucleoside analogs like cladribine or deoxycoformycin, which yield durable remissions though they may increase susceptibility to infections. Interferon-&alpha; has some efficacy but is less potent.</li>\n<li>Refractory cases have shown positive responses to the BRAF inhibitor <strong>vemurafenib</strong>, with even more sustained remissions when combined with rituximab.</li>\n<li>The disease follows an indolent course and responds well to re-treatment, contributing to its overall excellent prognosis.</li>\n</ul>\n<p><strong>Explanations of other options:</strong></p>\n<p><strong>Acute lymphoid leukemia (Option A):</strong> Acute lymphoblastic leukemia (ALL) is a malignancy of immature lymphoid cells, primarily affecting <strong>children</strong>. Peripheral smear typically reveals <strong>lymphoblasts</strong> with condensed nuclear chromatin, small nucleoli, and scant basophilic cytoplasm.</p>\n<p><strong>Idiopathic thrombocytopenic purpura (Option B):</strong> Immune thrombocytopenic purpura (ITP) is a condition marked by<strong> immune-mediated destruction</strong> of platelets and occasionally impaired platelet production. In children, it often follows an infection and resolves spontaneously, while in adults, it tends to be chronic or associated with secondary causes like autoimmune diseases or infections. Clinically, it presents with mucocutaneous bleeding and marked thrombocytopenia, while peripheral smear typically reveals <strong>large platelets</strong> with otherwise normal morphology.</p>\n<p><strong>Infectious mononucleosis (Option D):</strong> Infectious mononucleosis, caused by a new EBV infection, typically affects <strong>young adults</strong> and is characterized by malaise, fever, sore throat, and prominent <strong>cervical lymphadenopathy</strong>. Physical findings often include posterior cervical or auricular lymph node enlargement, <strong>splenomegaly</strong>, and exudative pharyngitis with palatine petechiae and a gelatinous uvula. Hematologic features include <strong>lymphocytosis</strong> with &gt;50% lymphocytes, of which &gt;10% show atypical morphology, and diagnosis is supported by detection of heterophil antibodies, which become positive in the majority of cases by the third week.</p>",
      "correct_choice_id": 152,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 17,
      "choices": [
        {
          "id": 161,
          "text": "<p><span style=\"font-size:12.0pt;\">Dexamethasone</span></p>"
        },
        {
          "id": 162,
          "text": "<p><span style=\"font-size:12.0pt;\">Antibiotics</span></p>"
        },
        {
          "id": 163,
          "text": "<p><span style=\"font-size:12.0pt;\">ATRA</span></p>"
        },
        {
          "id": 164,
          "text": "<p><span style=\"font-size:12.0pt;\">Arsenic trioxide</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A young girl with acute promyelocytic leukemia develops tachypnea, weight gain and fever on day 3 of treatment. CXR shows bilateral pulmonary infiltrates. What is the best management for the patient?</span></p>",
      "unique_key": "DT1198267",
      "question_audio": null,
      "question_video": null,
      "map_id": 1198267,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p>The given clinical scenario is consistent with<strong> differentiation syndrome</strong> seen in acute promyelocytic leukemia after treatment with <strong>all-trans retinoic acid (ATRA)</strong> which is treated with <strong>dexamethasone</strong>.</p>\n<ul>\n<li><strong>Acute promyelocytic leukemia</strong> is a treatable AML subtype with high cure rates, especially due to the introduction of all-trans retinoic acid (ATRA), which promotes differentiation of leukemic cells with the<strong> t(15;17)</strong></li>\n<li>ATRA has significantly reduced early deaths from DIC, though it can cause APL (differentiation) syndrome. (Option C ruled out)</li>\n<li>APL syndrome typically arises within the<strong> first three weeks </strong>of initiating treatment and presents with symptoms such as fever, fluid buildup, breathing difficulty, chest discomfort, lung infiltrates, and pleural or pericardial effusions, often accompanied by low oxygen levels.</li>\n<li>The condition results from the <strong>adherence of differentiated leukemic cells</strong> to the pulmonary blood vessel lining.</li>\n<li>Management involves<strong> glucocorticoids</strong>, cytoreductive chemotherapy, and supportive care. (Option B ruled out)</li>\n<li>In severe cases, such as when patients develop kidney failure or require ICU admission for respiratory distress, ATRA should be temporarily withheld.</li>\n<li>The syndrome has an approximate mortality rate of 10% and can occasionally also be triggered by arsenic trioxide (ATO) therapy in APL. (Option D ruled out)</li>\n</ul>",
      "correct_choice_id": 161,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 18,
      "choices": [
        {
          "id": 171,
          "text": "<p><span style=\"font-size:12.0pt;\">ALL</span></p>"
        },
        {
          "id": 172,
          "text": "<p><span style=\"font-size:12.0pt;\">CML</span></p>"
        },
        {
          "id": 173,
          "text": "<p><span style=\"font-size:12.0pt;\">CLL</span></p>"
        },
        {
          "id": 174,
          "text": "<p><span style=\"font-size:12.0pt;\">AML</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">L-Asparaginase is used in the treatment of?</span></p>",
      "unique_key": "DT1198268",
      "question_audio": null,
      "question_video": null,
      "map_id": 1198268,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p>L-asparaginase is used in the treatment of ALL.</p>\n<ul>\n<li>Treatment of acute lymphoblastic leukemia (ALL) generally involves <strong>four stages</strong>: pre-phase therapy, induction, consolidation, and maintenance.</li>\n<li><strong>Pre-phase therapy</strong> with glucocorticoids (prednisone or dexamethasone) alone or in combination with agents like vincristine or cyclophosphamide is given for 5-7 days to prevent tumor lysis syndrome, initiate supportive care, and allow time for diagnostics.</li>\n<li><strong>Induction</strong> aims for complete or molecular remission and includes vincristine, glucocorticoids, anthracyclines, and possibly cyclophosphamide or cytarabine.</li>\n<li>L-asparaginase is a key agent in treating ALL, as lymphoid leukemia cells rely on external sources of asparagine.</li>\n<li>The drug works by <strong>hydrolyzing circulating asparagine</strong> to aspartic acid and ammonia, thus depriving tumor cells of this essential amino acid and inducing cell death.</li>\n<li>Pegaspargase, a PEGylated form, offers a longer half-life and reduced immunogenicity, allowing administration every 14 days, while calaspargase pegol lasts up to 21 days.</li>\n<li><strong>Consolidation</strong> typically involves six to eight cycles of high-dose methotrexate and/or cytarabine to achieve therapeutic levels in sanctuary sites such as the CNS.</li>\n<li><strong>Maintenance therapy</strong>, essential even in adults, includes 6-mercaptopurine, methotrexate, and intrathecal treatment, with tyrosine kinase inhibitors added in Ph+ cases. Maintenance lasts 2 - 2.5 years, guided by MRD monitoring, and tyrosine kinase inhibitors may be adjusted based on tolerability.</li>\n</ul>\n<p><strong>Explanations of other options:</strong></p>\n<p><strong>CML (Option B): </strong>Medical treatment in CML include tyrosine kinase inhibitors and Omacetaxine mepesuccinate</p>\n<p><strong>CLL (Option C): </strong>Currently, the majority of patients receive oral treatments directed at BTK or BCL2, either alone or in combination with a CD20 monoclonal antibody.</p>\n<p><strong>AML (Option D): </strong>The main drugs used in AML treatment include <strong>cytarabine</strong> and <strong>anthracyclines</strong> (such as daunorubicin or idarubicin) as the backbone of induction therapy.</p>",
      "correct_choice_id": 171,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19,
      "choices": [
        {
          "id": 181,
          "text": "<p><span style=\"font-size:12.0pt;\">Blood cultures</span></p>"
        },
        {
          "id": 182,
          "text": "<p><span style=\"font-size:12.0pt;\">Flow cytometry</span></p>"
        },
        {
          "id": 183,
          "text": "<p><span style=\"font-size:12.0pt;\">Gene analysis for G6PD deficiency</span></p>"
        },
        {
          "id": 184,
          "text": "<p><span style=\"font-size:12.0pt;\">Donath-Landsteiner antibody</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 47-year-old woman comes to your OPD with complaints of passing blood in urine in the mornings. She denies any other symptoms except for occasional recurrent attacks of severe abdominal pain for which she has had other urgent care visits but no etiology was found. She has no other past medical history. You repeat a complete blood count. The results are below: White blood cell count 2900/mm<sup>3</sup><br>Hemoglobin 10.2 g/dL<br>Platelet count 119000/mm<sup>3</sup><br>Her complete blood count 1 year ago was normal. Investigations also revealed elevated unconjugated bilirubin and a markedly elevated lactate hydrogenase. Which of the following diagnostic test results would you consider in this patient?</span></p>",
      "unique_key": "DT1198272",
      "question_audio": null,
      "question_video": null,
      "map_id": 1198272,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p>This patient presents with the classic signs, symptoms, and laboratory abnormalities of paroxysmal nocturnal hemoglobinuria (PHN) which is diagnosed by <strong>flow cytometry</strong>.</p>\n<ul>\n<li>PNH is an <strong>acquired chronic hemolytic anemia</strong> characterized by persistent <strong>intravascular hemolysis</strong>, sometimes punctuated by <strong>recurrent exacerbations</strong>.</li>\n<li>It commonly presents with a triad of<strong> hemolysis</strong>, cytopenias, and a predisposition to venous thrombosis.</li>\n<li>Diagnosis is often delayed due to variable manifestations, though it is confirmed through laboratory investigations. It affects <strong>both sexes equally</strong>, can occur at any age but often arises in young adults, and is not inherited.</li>\n<li>Patients may report<strong> passing dark or blood-stained urine</strong>, typically in the morning, though this is not always noticed.</li>\n<li>Many present with nonspecific signs of anemia, which may be discovered incidentally. Cytopenias such as <strong>neutropenia</strong> and<strong> thrombocytopenia</strong> may indicate marrow involvement.</li>\n<li><strong>Abdominal pain</strong> may occur due to thrombosis, and hepatic vein thrombosis may result in Budd-Chiari syndrome.</li>\n<li>Thrombosis is a major cause of death in PNH.</li>\n<li>Bone marrow findings often reveal <strong>erythroid hyperplasia</strong>, but in some cases may be hypocellular or aplastic. Laboratory features include normocytic or macrocytic anemia, <strong>elevated LDH</strong>, low haptoglobin, and hemoglobinuria.</li>\n<li>The disorder arises from a somatic mutation in the<strong> PIGA </strong>gene affecting the GPI anchor, which results in deficient expression of surface proteins like<strong> CD55 </strong>and <strong>CD59 </strong>that normally protect red cells from complement.</li>\n<li>This leads to uncontrolled <strong>complement-mediated hemolysis</strong>. The absence of CD59 particularly contributes to <strong>formation of the membrane attack complex (MAC)</strong>, causing red cell lysis.</li>\n<li>Platelet activation due to CD59 deficiency also contributes to thrombosis.</li>\n<li><strong>Flow cytometry</strong> is the <strong>diagnostic gold standard</strong>, identifying the absence of GPI-anchored proteins on granulocytes and red cells. A PNH diagnosis requires at least 5% of red cells and 20% of granulocytes lacking these proteins.</li>\n<li>Historically, treatment options were limited to bone marrow transplantation or supportive care. Introduction of <strong>eculizumab</strong>, a monoclonal antibody against C5, has significantly improved outcomes by reducing hemolysis and thrombosis. Bone marrow transplantation is still considered for young patients or those with marrow failure.</li>\n</ul>\n<p><strong>Explanations of other options:</strong></p>\n<p><strong>Blood cultures (Option A): </strong>Blood cultures would identify septicemia which can contribute to intravascular hemolysis. The clinical features in the given scenario does not suggest sepsis.</p>\n<p><strong>Gene analysis for G6PD deficiency (Option C): </strong>Mutations in the 6-phosphate dehydrogenase (G6PD) gene lead to G6PD deficiency, which can lead to hemolysis with certain drugs, fava beans, and other <strong>oxidative agents</strong>.</p>\n<p><strong>Donath-Landsteiner antibody (Option D): Paroxysmal cold hemoglobinuria</strong> is a rare type of autoimmune hemolytic anemia (AIHA) that mainly affects<strong> children </strong>and is often preceded by a viral infection. It is usually a self-limiting condition and is identified by the presence of the Donath-Landsteiner antibody, which typically targets the P antigen on red cells.</p>",
      "correct_choice_id": 182,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20,
      "choices": [
        {
          "id": 191,
          "text": "<p><span style=\"font-size:12.0pt;\">Isolated abnormal prothrombin time (PT)</span></p>"
        },
        {
          "id": 192,
          "text": "<p><span style=\"font-size:12.0pt;\">Isolated activated partial thromboplastin time (aPTT)</span></p>"
        },
        {
          "id": 193,
          "text": "<p><span style=\"font-size:12.0pt;\">Prolongation of both PT and aPTT</span></p>"
        },
        {
          "id": 194,
          "text": "<p><span style=\"font-size:12.0pt;\">Normal PT and aPTT</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Factor VII deficiency should be considered with which of the following coagulation abnormalities?</span></p>",
      "unique_key": "DT1198275",
      "question_audio": null,
      "question_video": null,
      "map_id": 1198275,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p>Factor VII deficiency should be considered with isolated abnormal prothrombin time.</p>\n<ul>\n<li>Deficiencies in coagulation factors, especially inherited forms, have long been identified as causes of recurrent spontaneous or post-traumatic bleeding into joints, muscles, and body cavities.</li>\n<li>The most common inherited forms are hemophilia A (deficiency of factor VIII) and hemophilia B (deficiency of factor IX), both of which follow an X-linked inheritance pattern.</li>\n<li>Additional congenital bleeding disorders may involve deficiencies in factors such as prothrombin (FII), FV, FVII, FX, FXI, FXIII, and fibrinogen, which tend to follow autosomal recessive inheritance.</li>\n<li>Factor levels often correlate with disease severity. Some individuals with <strong>significant prolongation of aPTT</strong>, like those deficient in FXII, may not exhibit bleeding due to compensatory mechanisms within the coagulation cascade.</li>\n<li>The initial screening for factor deficiencies usually involves prothrombin time (PT) and activated partial thromboplastin time (aPTT).</li>\n<li>A <strong>prolonged PT alone points to FVII deficiency</strong>, while an isolated prolonged aPTT suggests <strong>intrinsic pathway deficiencies like FVIII </strong>(hemophilia A), <strong>FIX </strong>(hemophilia B), or <strong>FXI</strong>. (Options B and D ruled out)</li>\n<li>If both PT and aPTT are prolonged, broader abnormalities such as<strong> FV</strong>, <strong>FX</strong>, FII, or fibrinogen deficiency may be suspected. (Option C ruled out)</li>\n<li>A <strong>mixing study</strong>, where normal plasma is added to patient plasma, helps distinguish between true factor deficiencies and inhibitors or anticoagulants. If clotting time normalizes, a deficiency is likely while <strong>failure to normalize</strong> implies the presence of an <strong>inhibitor</strong>.</li>\n<li>Development of inhibitors (alloantibodies) against coagulation factors is rare but can occur in hemophilia A or B, or FXI deficiency, particularly after repeated factor replacement.</li>\n<li>Some autoimmune or idiopathic settings, as well as postpartum states, may also lead to inhibitor formation.</li>\n<li>Acquired factor deficiencies are more common than inherited forms and include those due to <strong>liver disease</strong>, DIC, or vitamin K deficiency, which typically involve multiple clotting factor deficits.</li>\n</ul>",
      "correct_choice_id": 191,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 21,
      "choices": [
        {
          "id": 201,
          "text": "<p><span style=\"font-size:12.0pt;\">30%</span></p>"
        },
        {
          "id": 202,
          "text": "<p><span style=\"font-size:12.0pt;\">10%</span></p>"
        },
        {
          "id": 203,
          "text": "<p><span style=\"font-size:12.0pt;\">5%</span></p>"
        },
        {
          "id": 204,
          "text": "<p><span style=\"font-size:12.0pt;\">1%</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Severe Hemophilia A is defined as factor 8 levels below?</span></p>",
      "unique_key": "DT1198282",
      "question_audio": null,
      "question_video": null,
      "map_id": 1198282,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<ul>\n<li><strong>Hemophilia</strong> is an<strong> X-linked recessive</strong> bleeding disorder caused by mutations in the F8 gene (hemophilia A) or F9 gene (hemophilia B), with hemophilia A accounting for about 80% of cases.</li>\n<li>Males are usually symptomatic, while female carriers are typically asymptomatic.</li>\n<li>A common mutation in severe hemophilia A involves an<strong> inversion in intron 22</strong>. Clinically, hemophilia A and B appear identical, with severity categorized based on factor VIII or IX activity levels:</li>\n</ul>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V2NEETPGMCQ/20240327d775337d-e673-4dc7-9f10-a85df199eafa.jpg\">\n<ul>\n<li>Severe and moderate forms frequently present with spontaneous or trauma-induced bleeding into<strong> joints</strong> (hemarthrosis), <strong>muscles</strong>, or soft tissues.</li>\n<li>Mild cases usually only bleed after major trauma or surgery. Bleeding into joints may lead to joint pain, swelling, and <strong>progressive deformities</strong>. Hemorrhages may also affect muscles, leading to compartment syndrome.</li>\n<li>Serious complications include bleeding into the CNS, retroperitoneum, and oropharyngeal spaces, which can be life-threatening. Retroperitoneal bleeds may form calcified masses (pseudotumors) that compress nearby structures, such as the femoral nerve or bones.</li>\n</ul>",
      "correct_choice_id": 204,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 22,
      "choices": [
        {
          "id": 211,
          "text": "<p><span style=\"font-size:12.0pt;\">Eculizumab</span></p>"
        },
        {
          "id": 212,
          "text": "<p><span style=\"font-size:12.0pt;\">Adalimumab</span></p>"
        },
        {
          "id": 213,
          "text": "<p><span style=\"font-size:12.0pt;\">Emicizumab</span></p>"
        },
        {
          "id": 214,
          "text": "<p><span style=\"font-size:12.0pt;\">Abciximab</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following monoclonal antibodies is approved for patients with hemophilia A with or without inhibitors?</span></p>",
      "unique_key": "DT1198284",
      "question_audio": null,
      "question_video": null,
      "map_id": 1198284,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>Explanation:</strong></p>\n<p><strong>Emicizumab is a monoclonal antibody </strong>approved for patients with hemophilia A with or without inhibitors</p>\n<ul>\n<li>Emicizumab is a bispecific monoclonal antibody that<strong> bridges activated factor IX</strong> (FIXa) and<strong> factor X</strong> (FX), enabling the activation of FX by FIXa without the involvement of factor VIII (FVIII).</li>\n<li>This mimics the function of FVIII and allows thrombin generation and clot formation. It is particularly effective in patients with <strong>severe hemophilia A</strong>, including those who have developed <strong>FVIII inhibitors</strong>.</li>\n<li>Treatment begins with <strong>weekly subcutaneous injections </strong>for four weeks, followed by maintenance dosing once a month to prevent spontaneous bleeding episodes.</li>\n<li>This regimen offers a substantial improvement in quality of life compared to traditional intravenous FVIII infusions.</li>\n<li>However, caution is required, as rare <strong>thrombotic event</strong>s and fatal thrombotic microangiopathy have been reported in patients receiving bypassing agents like activated prothrombin complex concentrate (aPCC) or recombinant FVIIa in conjunction with emicizumab.</li>\n</ul>\n<p><strong>Explanations of other options:</strong></p>\n<p><strong>Eculizumab (Option A): </strong>Eculizumab is a monoclonal antibody that targets complement protein C5, thereby blocking the formation of the membrane attack complex (C5b-9). It is employed in the management of <strong>atypical hemolytic uremic syndrome</strong> and <strong>paroxysmal nocturnal hemoglobinuria</strong>.</p>\n<p><strong>Adalimumab (Option B): </strong>Adalimumab is a genetically engineered monoclonal antibody that targets tumor necrosis factor-alpha (TNF-&alpha;) and is utilized in the treatment of autoimmune disorders such as <strong>Crohn&rsquo;s disease</strong> and <strong>rheumatoid arthritis</strong>.</p>\n<p><strong>Abciximab (Option C): </strong>Abciximab is an inhibitor of glycoprotein IIb/IIIa receptors that blocks platelet aggregation and is employed in treating acute coronary syndromes, particularly during percutaneous coronary interventions.</p>",
      "correct_choice_id": 213,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 23,
      "choices": [
        {
          "id": 221,
          "text": "<p><span style=\"font-size:12.0pt;\">B12 deficiency</span></p>"
        },
        {
          "id": 222,
          "text": "<p><span style=\"font-size:12.0pt;\">Aplastic Anemia</span></p>"
        },
        {
          "id": 223,
          "text": "<p><span style=\"font-size:12.0pt;\">Hypothyroidism</span></p>"
        },
        {
          "id": 224,
          "text": "<p><span style=\"font-size:12.0pt;\">Copper deficiency</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following is not a cause of non-megaloblastic macrocytic anemia?</span></p>",
      "unique_key": "DT1198288",
      "question_audio": null,
      "question_video": null,
      "map_id": 1198288,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><strong>B12 deficiency</strong> results in <strong>megaloblastic macrocytic anemia</strong>.</p>\n<p>Macrocytic anemia can be due to megaloblastic or non-megaloblastic causes as given below.</p>\n<img class=\"w-100\" style=\"height:auto; display:block; vertical-align:middle; border:0; \"src=\"https://d3d535v34tlady.cloudfront.net/V2NEETPGMCQ/20240327b00c274a-95f3-49c9-b20f-985edb799b1c.jpg\">",
      "correct_choice_id": 221,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    }
  ]
}